These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 23214190)

  • 1. Cardiotoxicity of oncological treatment in children.
    Kucharska W; Negrusz-Kawecka M; Gromkowska M
    Adv Clin Exp Med; 2012; 21(3):281-8. PubMed ID: 23214190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High risk of symptomatic cardiac events in childhood cancer survivors.
    van der Pal HJ; van Dalen EC; van Delden E; van Dijk IW; Kok WE; Geskus RB; Sieswerda E; Oldenburger F; Koning CC; van Leeuwen FE; Caron HN; Kremer LC
    J Clin Oncol; 2012 May; 30(13):1429-37. PubMed ID: 22473161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
    Jensen BV
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: a prospective follow-up study.
    Sieswerda E; Kremer LC; Vidmar S; De Bruin ML; Smibert E; Sjöberg G; Cheung MM; Weintraub RG
    Pediatr Blood Cancer; 2010 Apr; 54(4):579-84. PubMed ID: 20014238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of cardiotoxicity induced by anthracyclines.
    Elliott P
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group.
    Shankar SM; Marina N; Hudson MM; Hodgson DC; Adams MJ; Landier W; Bhatia S; Meeske K; Chen MH; Kinahan KE; Steinberger J; Rosenthal D;
    Pediatrics; 2008 Feb; 121(2):e387-96. PubMed ID: 18187811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III].
    Bustová I
    Klin Onkol; 2009; 22(1):17-21. PubMed ID: 19534435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemotherapy-induced cardiotoxicity: Incidence, diagnosis and prevention].
    Nelson-Veniard M; Thambo JB
    Bull Cancer; 2015; 102(7-8):622-6. PubMed ID: 25935231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [High-resolution electrocardiography in monitoring myocardial damage after therapy with anthracyclines in children].
    Mladosievicová B; Foltinová A; Bernadic M; Petrásová H; Hulín I
    Bratisl Lek Listy; 1996 May; 97(5):289-97. PubMed ID: 8705327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
    Pai VB; Nahata MC
    Drug Saf; 2000 Apr; 22(4):263-302. PubMed ID: 10789823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Present risk of anthracycline or radiation-induced cardiac sequelae following therapy of malignancies in children and adolescents.
    Chen C; Heusch A; Donner B; Janssen G; Göbel U; Schmidt KG
    Klin Padiatr; 2009; 221(3):162-6. PubMed ID: 19437364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnostic possibilities of late cardiotoxic sequelae of chemotherapy with anthracyclines].
    Elbl L; Hrstková H; Chaloupka V; Novotný J
    Vnitr Lek; 2002 Oct; 48(10):981-8. PubMed ID: 16737150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.
    Mavinkurve-Groothuis AM; Groot-Loonen J; Bellersen L; Pourier MS; Feuth T; Bökkerink JP; Hoogerbrugge PM; Kapusta L
    Pediatr Blood Cancer; 2009 May; 52(5):631-6. PubMed ID: 19127569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment-related cardiotoxicity in childhood cancer survivors: Risk factors and follow-up].
    Fresneau B; Fayech C; Butel T; Haddy N; Valteau-Couanet D; Ou P
    Rev Med Interne; 2017 Feb; 38(2):125-132. PubMed ID: 27639916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer therapy and cardiotoxicity: the need of serial Doppler echocardiography.
    Galderisi M; Marra F; Esposito R; Lomoriello VS; Pardo M; de Divitiis O
    Cardiovasc Ultrasound; 2007 Jan; 5():4. PubMed ID: 17254324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
    Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
    J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer agents and cardiotoxicity.
    Ng R; Better N; Green MD
    Semin Oncol; 2006 Feb; 33(1):2-14. PubMed ID: 16473642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cardiotoxicity of antracycline treatment in the light of new biochemical diagnostic options].
    Urbanová D; Mladosievicová B
    Vnitr Lek; 2007 Jun; 53(6):669-77. PubMed ID: 17702127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring of anthracycline-induced cardiotoxicity.
    Jannazzo A; Hoffman J; Lutz M
    Ann Pharmacother; 2008 Jan; 42(1):99-104. PubMed ID: 18094345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.